MIB-626
AssetSmall moleculeAlso beta-nicotinamide mononucleotide (MIB-626), β-nicotinamide mononucleotide (MIB-626)
Oral beta-nicotinamide mononucleotide NAD+ precursor enhancing NAD+ biosynthesis and mitochondrial function.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Oxidative phosphorylation
- Indications
- 5
- Trials
- 8
- Developers
- 1
Indications
5Alzheimer's disease
Phase 2metrobiotech.com7 Oct 2026
Covid19
Phase 2COMPLETEDNCT05038488clinicaltrials.gov7 Oct 2026
Diabetic kidney disease
Phase 2metrobiotech.com7 Oct 2026
2 more
- Targets and what it contains6
- Owner and partners2
- Trials8
- Evidence for its targets6
- Competitors12
- Aging relevance2
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 4 sources